No headlines found.
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Fri, 13-Mar 4:05 PM ET)
Business Wire (Thu, 5-Mar 4:05 PM ET)
Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference
Business Wire (Tue, 3-Mar 4:05 PM ET)
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
Contineum Therapeutics trades on the NASDAQ stock market under the symbol CTNM.
As of March 19, 2026, CTNM stock price declined to $12.08 with 10,589 million shares trading.
CTNM has a beta of -0.23, meaning it tends to be less sensitive to market movements. CTNM has a correlation of 0.00 to the broad based SPY ETF.
CTNM has a market cap of $441.28 million. This is considered a Small Cap stock.
Last quarter Contineum Therapeutics reported $0 in Revenue and -$.49 earnings per share. This fell short of revenue expectation by $-5 million and missed earnings estimates by -$.06.
The top ETF exchange traded funds that CTNM belongs to (by Net Assets): VTI, VXF, IBB, SCHA, IWC.
CTNM has outperformed the market in the last year with a return of +61.3%, while the SPY ETF gained +18.6%. In the last 3 month period, CTNM beat the market returning +6.1%, while SPY returned -2.2%. However, in the most recent 2 weeks CTNM has underperformed the stock market by returning -18.7%, while SPY returned -4.0%.
CTNM support price is $11.54 and resistance is $12.90 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CTNM shares will trade within this expected range on the day.
